This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Buprenorphine Dose Escalation Trial for Treatment of Non-Dependent Opiate Users - 2

This study has been completed.
Cincinnati MDRU
Information provided by:
National Institute on Drug Abuse (NIDA) Identifier:
First received: April 18, 2001
Last updated: January 11, 2017
Last verified: July 1998
The purpose of this study is to evaluate the effect, pharmacokinetics and dose proportionality of buprenorphine when administered to non-dependent opiate users. 1) To evaluate whether plasma concentrations of buprenorphine increase proportionally to buprenorphine dose. 2) To evaluate the dose-response of subjective and physiological effects of buprenorphine; and 3) To determine the safety of buprenorphine.

Condition Intervention Phase
Opioid-Related Disorders Substance-Related Disorders Drug: Buprenorphine Phase 1

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: PK 0396 - Buprenorphine Dose Escalation Trial

Resource links provided by NLM:

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • PK parameters of buprenorphine
  • Intoxication and withdrawal

Estimated Enrollment: 0
Study Start Date: November 1996
Study Completion Date: July 1998
Primary Completion Date: June 1998 (Final data collection date for primary outcome measure)
Detailed Description:

This will be an open-label, single dose-escalation trial. A total of 24 opiate experienced, but not dependent subjects will receive four ascending doses of buprenorphine, 4, 8, 16, and 24 mg, respectively, with an at least a 14 day washout interval between treatments. The four treatments are sublingual administration of:

  1. two 2-mg buprenorphine sublingual tablets,
  2. one 8-mg buprenorphine sublingual tablet,
  3. two 8-mg buprenorphine sublingual tablets; and
  4. three 8-mg buprenorphine sublingual tablets.

The dose proportionality in plasma profiles of buprenorphine and dose response of the buprenorphine sublingual tablets are evaluated at buprenorphine dose range of 4 to 24 mg.


Ages Eligible for Study:   21 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Be male or female of any race, between 21 and 45 years of age.
  2. Weigh within 15% of ideal body weight for height according to the current life insurance table.
  3. Be in good physical and mental health as judged by interview and physical examination.
  4. Have no significant oral cavity pathology including excessive caries, gingivitis, infectious or inflammatory disease, or recent piercing of the oral cavity.
  5. Be experienced in illicit use of opiates but not be physically dependent on opiates and other drugs (except nicotine or caffeine) at the time of the study. A history of other psychoactive drug use is acceptable but preference will be for subjects reporting less frequent and more controlled illicit drug use.
  6. For female subjects, test nonpregnant and use adequate birth control, and not be lactating.
  7. Be capable of providing written informed consent to participate in this study.
  8. Be able to comply with protocol requirements and be likely to complete all four study treatments.

Exclusion Criteria:

  1. Have a diagnosis of drug addiction (other than nicotine, caffeine, and opiate) as per DSM-IV criteria.
  2. Have any significant, active medical or psychiatric illnesses (other than drug dependence) which might inhibit their ability to complete the study or might be complicated by administration of study medications.
  3. Have clinically significant abnormal laboratory measurements in liver function tests (AST and ALT levels greater than 3 times the upper limit of normal), hematology (CBC, differential, platelet count), serum chemistries (SMA-24) and urinalysis at screening.
  4. Test positive on the HIV blood screen.
  5. Have a history of significant hepatic, renal, endocrine, cardiac, nervous, psychiatric, gastrointestinal, pulmonary, hematologic or metabolic disorders.
  6. Have known hypersensitivity to buprenorphine and its derivatives or opiates or opiate-like analgesics.
  7. Receive any medications for medical conditions.
  8. Have any condition or history considered by the investigator(s) to place the subjects at increased risk.
  9. Do not actively meet the inclusion criteria at the time of screening.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00015041

United States, Ohio
Cincinnati MDRU
Cincinnati, Ohio, United States, 45220
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Cincinnati MDRU
Principal Investigator: Eugene Somoza, M.D., Ph.D. Cincinnati MDRU
  More Information Identifier: NCT00015041     History of Changes
Other Study ID Numbers: NIDA-5-0012-2
Study First Received: April 18, 2001
Last Updated: January 11, 2017

Keywords provided by National Institute on Drug Abuse (NIDA):
opiate dependence

Additional relevant MeSH terms:
Substance-Related Disorders
Opioid-Related Disorders
Pathologic Processes
Chemically-Induced Disorders
Mental Disorders
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Narcotic Antagonists processed this record on July 19, 2017